MEDI-573

DRUG3 trials

Sponsors

MedImmune LLC, AstraZeneca

Conditions

Advanced Solid MalignanciesCancerHormone-sensitive, HER-2 Negative Metastatic Breast Cancer

Phase 1

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

CompletedNCT00816361

MedImmune LLCCancer

Start: 2009-03-09End: 2012-09-11Updated: 2019-03-04

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

CompletedNCT01340040

AstraZenecaAdvanced Solid Malignancies, Cancer

Start: 2011-07-31End: 2012-05-31Target: 10Updated: 2014-12-11

Phase 2

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

CompletedNCT01446159

MedImmune LLCHormone-sensitive, HER-2 Negative Metastatic Breast Cancer

Start: 2011-06-13End: 2019-06-28Updated: 2020-06-02